Caas Capital Management LP Biogen Inc. Put Options Transaction History

Caas Capital Management LP

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $974,928 - $1.11 Million	3,800 New	3,800 $1.06 Million
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $4.84 Million - $6.1 Million	-25,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $5.6 Million - $7.19 Million	25,000 New	25,000 $6 Million
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $267,245 - $313,093	-1,100 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $439,722 - $582,335	-1,700 Reduced 60.71%	1,100 $294,000
Q1 2020 May 15, 2020	BUY	$268.85 - $341.04 $752,780 - $954,912	2,800 New	2,800 $886,000

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.